Epitopea
Develops off-the-shelf RNA cancer immunotherapies for patients with difficult-to-treat cancers
Highlights
- New on EvolcAdded 2026-10-31
About Epitopea
Epitopea develops RNA-based cancer immunotherapies and uses its CryptoMap platform to identify shared, tumour-specific antigens for vaccine development.
Its pipeline targets cancer indications with high unmet medical need. The company is based in Cambridge, UK, and Montreal, Canada, with scientific teams in both cities.
Epitopea Limited was founded in 2021.
Product: CryptoMap antigen-discovery platform and a pipeline of RNA-based cancer immunotherapies.
Jobs at Epitopea
No open positions listed right now.
More biotech & pharma companies
Epsilogen
Develops antibody-based cancer treatments, including a clinical candidate for ovarian cancerNew on EvolcExtracellular
CDMO for cell-based food, cosmetics and materials products, offering bioprocess development and up to 2,000L manufacturingNew on EvolcSalary transparentExymes
Enzyme-based DNA/RNA extraction reagents and kits for forensic, academic, veterinary and environmental labsYoung companyNew on EvolcF2G
Develops first-in-class antifungal medicines for rare, life-threatening fungal infections in patients with limited optionsNew on EvolcFlyttr
Pest biosecurity platform with sensors, AI decision-support and biological countermeasures for governments and agricultureNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Google Analytics 4
- WordPress
- jQuery
- nginx
